Fig 1: Inhibition of Mouse CRC Progression by Targeting Tumor-expressing CCR6.(A) Western blotting analysis of CCR6 in murine CMT93 colorectal tumor cell line and CRC tissue derived from CCR6−/− mice grafted with CMT93 at day10. (B) Statistical analysis of tumor weight in each group treated with IgG or anti-CCR6. (C) Western blotting of CCR6 in murine CT26 colorectal tumor cell line and CRC tissue derived from Balb/c mice grafted with CT26 at day 10. (D) Statistical analysis of tumor weight in each group treated with IgG or anti-CCR6. *p<0.05, **p<0.01, U-mann whitney test.
Fig 2: Pathologic findings of DLBCL with expression of five candidate genes. (A) BLS-type DLBCL shows patchy or interstitial infiltration by tumor cells in the bone marrow without sinusoidal involvement (HE stain, 100X). The centroblast-like tumor cells show large, vesicular nuclei with one to several prominent nucleoli (inset, 400X). (B) Immunohistochemical analysis showed that the lymphoma cells involving bone marrow express NANOG in the cytoplasm in contrast to the negative hematopoietic elements (100X; inset, 400X). (C) Lymphoma cells in this nodal case are positive for HOXA9 in nuclei (100X; inset, 400X). (D) S100A8 (MRP8) is positive in the cytoplasm of tumor cells of a nodal case (400X). (E) This case of BLS-type DLBCL involving bone marrow expresses cytoplasmic BMP8B (400X). (F) This nodal case expresses CCR6 in cytoplasm (400X).
Fig 3: B cells with higher CCR6 expression have higher chemotactic ability. (A) Relative expression levels of CCR6 protein in six B cell lines. (B) Chemotaxis assay shows that B cells with higher CCR6 expression have higher chemotactic migration ability for CCL20. (C–H) Examples of cell migration (C, E, G: 0 ng/mL of CCL20; D, F, H: 500 ng/mL of CCL20; C-D: LCL; E–F: HT; G-H: SU-DHL-5). *p < 0.05, **p < 0.01, ***p < 0.001, Student paired t-test.
Fig 4: CCR6 is expressed on macrophages. Untreated, uninfected MDM were harvested and stained for flow cytometry analysis of CCR6 as described in Materials and Methods. Data analyses were performed using FlowJo software. Forward scatter dot plots show the fluorescence and percentage of cells positive for CCR6 as compared to the respective isotype-matched control. A representative of each type (A) CCR6-, (B) CCR6+/-, and (C) CCR6+ is shown. (D) Median Fluorescence Intensity (MFI) values for CCR6 surface expression (as compared to MFI for isotype control) on MDM from different donors designated as either CCR6-, CCR6+/-, or CCR6+. Data are presented as median and range of MFI values. Each dot represents one donor. ****P < 0.0001 between CCR6+/- and CCR6- or CCR6+ and CCR6- determined with unpaired two-tailed t test. (E) Immunoblot analysis of CCR6 on MDM from 3 donors, 1 day and 10 days of tissue culture without treatment. JKT-FT CCR6 GFP cell line lysate in first lane from left is used as a positive control; the second lane is empty; subsequent lanes are donors #1-3, at day 1 and day 10 of tissue culture.
Fig 5: Effect of anti-CCL20 antibody or CCR6 knock down on microgliosis and astrogliosis in optic nerve following rTBI. a Representative immunofluorescence images showing Iba1 (red) or GFAP (green) immunoreactivity in the optic nerve. Scale bar 100 μm. b, c Histograms showing average count of Iba1-positive cells (b) or average fluorescence intensity of GFAP immunoreactivity (c) as quantitated by ImageJ. Values are shown as mean ± SEM. *p < 0.01, **p < 0.001, ***p < 0.0001
Supplier Page from Abcam for Anti-CCR6 antibody